An Overview of a Phase II Study of ONT-380 in HER2-Positive Breast Cancer

December 22, 2016
Mark D. Pegram, MD

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women’s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses a phase II trial looking at ONT-380 in HER2+ breast cancer.